Your browser doesn't support javascript.
loading
Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature.
Aoki, Masato; Takaya, Hisamitsu; Otani, Tomoyuki; Nakai, Hidekatsu; Murakami, Kosuke; Matsumura, Noriomi.
Affiliation
  • Aoki M; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.
  • Takaya H; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.
  • Otani T; Department of Pathology, Kindai University Faculty of Medicine, Osakasayama, Osaka Japan.
  • Nakai H; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.
  • Murakami K; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.
  • Matsumura N; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, 377-2, Ohno-higashi, Osakasayama, Osaka Japan.
Int Cancer Conf J ; 11(4): 231-237, 2022 Oct.
Article in En | MEDLINE | ID: mdl-36186232
ABSTRACT
Ovarian teratoid carcinosarcoma involves an epithelial tumor of the Müllerian duct and an immature neuroepithelium, which is a characteristic of immature teratomas. Here, we describe the case of a 60-year-old woman who underwent surgery for a stage IC3 ovarian malignancy. The tumor showed a variety of histological features, including clear cell carcinoma, immature teratoma, and rhabdomyosarcoma, and a PIK3CA mutation was detected at the same locus in each. Two months after surgery and before the start of chemotherapy, multiple bone and liver metastases were found. Four courses of combination therapy with vincristine, actinomycin D and cyclophosphamide, the standard chemotherapy regimen for pediatric rhabdomyosarcoma, were administered, and a complete response was achieved. After a 2-month rest period, the patient developed recurrent peritoneal dissemination and underwent 6 courses of paclitaxel, carboplatin, and bevacizumab chemotherapy, resulting in a partial response. This is the eighth reported case of ovarian teratoid carcinosarcoma. This tumor has a very aggressive course, but initially responds to chemotherapy. However, survival over 5 years has not been reported, and elucidation of the pathogenesis and development of new treatment methods are needed. Supplementary Information The online version contains supplementary material available at 10.1007/s13691-022-00571-w.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int Cancer Conf J Year: 2022 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int Cancer Conf J Year: 2022 Document type: Article
...